Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,906,945 shares of the specialty pharmaceutical company’s stock after selling 183,927 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Jazz Pharmaceuticals worth $778,535,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of JAZZ. Farther Finance Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares during the last quarter. Quent Capital LLC purchased a new position in Jazz Pharmaceuticals during the third quarter worth about $44,000. Hantz Financial Services Inc. boosted its holdings in Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 30.7% in the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 154 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $172.19 on Monday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The company has a market cap of $10.46 billion, a P/E ratio of -28.37, a P/E/G ratio of 0.93 and a beta of 0.26. The stock has a 50-day moving average of $167.92 and a two-hundred day moving average of $149.40. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $182.99.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the sale, the chief accounting officer owned 7,012 shares in the company, valued at $1,200,454.40. This represents a 39.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the transaction, the senior vice president owned 19,508 shares of the company’s stock, valued at $3,306,801.08. The trade was a 10.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 84,398 shares of company stock worth $14,957,430 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Piper Sandler restated an “overweight” rating and issued a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Morgan Stanley reissued an “overweight” rating and set a $225.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Fourteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.